diff --git a/pages/InCORNTD 2025___Application.md b/pages/InCORNTD 2025___Application.md
index f982d5aa..184fab77 100644
--- a/pages/InCORNTD 2025___Application.md	
+++ b/pages/InCORNTD 2025___Application.md	
@@ -1,9 +1,9 @@
 # [[2024/10/30]]
 	- **Título**: Fixed dose albenzadole/ivermectin coformulation, an innovative tool to help countries achieve their NTD control goals in a post-donation era
 	- #+BEGIN_VERSE
-	  **Description**: The fixed-dose coformulation (FDC) of albendazole and ivermectin is the result of more than years of innovations carried out by African and European organizations working through public-private partnerships. 
+	  **Description**: The fixed-dose coformulation (FDC) of albendazole and ivermectin is the result of more than 10 years of innovations carried out by African and European organizations working through public-private partnerships. 
 	  
-	  This orodispersible, mango-flavoured tablet has already demonstrated safety and efficacy against soil-transmitted helminths in a 2022/2023 phase II/III pivotal trial and is currently under evaluation by the European Medicines Agency (EMA) under the EU-M4All procedure and Ghana's FDA for registration.
+	  This orodispersible, mango-flavoured tablet has already demonstrated safety and efficacy against soil-transmitted helminths in a 2022/2023 phase II/III pivotal trial. The results are already accepted for publication in Lancet Infectious Diseases and are currently under evaluation by the European Medicines Agency (EMA) under the EU-M4All procedure and Ghana's FDA for registration.
 	  
 	  The fixed-dose combination of albendazole and ivermectin provides a novel approach to mass drug administration campaigns that simplifies logistics while providing control abilities for more parasites. It allows for a more targeted approach
 	  #+END_VERSE